Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now at least
Novo Nordisk's obesity drug Wegovy is launching in Ireland, but patients will likely need to pay out-of-pocket, similar to Eli Lilly's Mounjaro. Wegovy, containing the same active ingredient as Ozempic in a higher dose, is approved for adults with a BMI of 30 or 27 with weight-related health issues. While Ireland is a strategic location for Novo Nordisk's manufacturing, Wegovy's reimbursement application remains unapproved and only Saxenda is currently approved for weight management in Ireland. A month's supply could cost around €290-€350, similar to the US cash price.
